These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 31975160)
1. Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study. Joshi S; Rathore AS BioDrugs; 2020 Apr; 34(2):209-223. PubMed ID: 31975160 [TBL] [Abstract][Full Text] [Related]
2. In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate. Chen L; Wang L; Shion H; Yu C; Yu YQ; Zhu L; Li M; Chen W; Gao K MAbs; 2016 Oct; 8(7):1210-1223. PubMed ID: 27380163 [TBL] [Abstract][Full Text] [Related]
3. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935 [TBL] [Abstract][Full Text] [Related]
4. Assessment of structural and functional similarity of biosimilar products: Bevacizumab as a case study. Bhattacharya S; Rathore AS J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Sep; 1229():123896. PubMed ID: 37776677 [TBL] [Abstract][Full Text] [Related]
5. Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study. Nupur N; Chhabra N; Dash R; Rathore AS MAbs; 2018 Jan; 10(1):143-158. PubMed ID: 29200314 [TBL] [Abstract][Full Text] [Related]
6. Assessing analytical comparability of biosimilars: GCSF as a case study. Nupur N; Singh SK; Narula G; Rathore AS J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():165-171. PubMed ID: 27289250 [TBL] [Abstract][Full Text] [Related]
8. Physicochemical and biological characterization of a biosimilar trastuzumab. López-Morales CA; Miranda-Hernández MP; Juárez-Bayardo LC; Ramírez-Ibáñez ND; Romero-Díaz AJ; Piña-Lara N; Campos-García VR; Pérez NO; Flores-Ortiz LF; Medina-Rivero E Biomed Res Int; 2015; 2015():427235. PubMed ID: 26075238 [TBL] [Abstract][Full Text] [Related]
9. Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar. Kim S; Song J; Park S; Ham S; Paek K; Kang M; Chae Y; Seo H; Kim HC; Flores M MAbs; 2017; 9(4):704-714. PubMed ID: 28296619 [TBL] [Abstract][Full Text] [Related]
10. Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment. Lee JH; Paek K; Moon JH; Ham S; Song J; Kim S BioDrugs; 2019 Aug; 33(4):411-422. PubMed ID: 31190280 [TBL] [Abstract][Full Text] [Related]
11. Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab. Hutterer KM; Polozova A; Kuhns S; McBride HJ; Cao X; Liu J BioDrugs; 2019 Jun; 33(3):321-333. PubMed ID: 30972630 [TBL] [Abstract][Full Text] [Related]
12. Analytic characterization of biosimilars. Sullivan PM; DiGrazia LM Am J Health Syst Pharm; 2017 Apr; 74(8):568-579. PubMed ID: 28389456 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses. Lee J; Kang HA; Bae JS; Kim KD; Lee KH; Lim KJ; Choo MJ; Chang SJ MAbs; 2018; 10(4):547-571. PubMed ID: 29482416 [TBL] [Abstract][Full Text] [Related]
14. Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars. Kang J; Halseth T; Vallejo D; Najafabadi ZI; Sen KI; Ford M; Ruotolo BT; Schwendeman A Anal Bioanal Chem; 2020 Jan; 412(3):763-775. PubMed ID: 31853605 [TBL] [Abstract][Full Text] [Related]
15. Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar. Cerutti ML; Pesce A; Bès C; Seigelchifer M BioDrugs; 2019 Jun; 33(3):307-319. PubMed ID: 30927214 [TBL] [Abstract][Full Text] [Related]
16. Comparison of originator and biosimilar monoclonal antibodies using HRMS, Fc affinity chromatography, and 2D-HPLC. Reinders LMH; Klassen MD; Teutenberg T; Jaeger M; Schmidt TC Anal Bioanal Chem; 2022 Sep; 414(23):6761-6769. PubMed ID: 35895102 [TBL] [Abstract][Full Text] [Related]
17. QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®. Jaffar-Aghaei M; Khanipour F; Maghsoudi A; Sarvestani R; Mohammadian M; Maleki M; Havasi F; Rahmani H; Karagah AH; Kazemali MR Eur J Pharm Sci; 2022 Jun; 173():106171. PubMed ID: 35378209 [TBL] [Abstract][Full Text] [Related]
18. Assessing the Structural and Functional Similarity of Insulin Glargine Biosimilars. Vishwakarma G; Nupur N; Rathore AS J Diabetes Sci Technol; 2023 Mar; 17(2):417-427. PubMed ID: 34852652 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive Physicochemical and Biological Characterization of the Proposed Biosimilar Darbepoetin Alfa, LBDE, and Its Originator Darbepoetin Alfa, NESP Jeong YR; Jeong RU; Son JH; Kwon JC; Jung S; Song MA; Hwang JA; Lee GM BioDrugs; 2018 Apr; 32(2):153-168. PubMed ID: 29556960 [TBL] [Abstract][Full Text] [Related]
20. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics. Sörgel F; Schwebig A; Holzmann J; Prasch S; Singh P; Kinzig M BioDrugs; 2015 Apr; 29(2):123-31. PubMed ID: 25837839 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]